EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Immune checkpoint blockade for cancer therapy: current progress and perspectives

Hongying Ye, Weijie Liao, Jiongli Pan, Yin Shi, Qingqing Wang

Journal of Zhejiang University-SCIENCE B · 2025-03 · 26 (3) · 203-226

DOI: 10.1631/jzus.b2300492 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Zhejiang University-SCIENCE B, online erschienen am 20.03.2025. Verfasst von Hongying Ye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National Key Research and Development Program of China, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysfunction of anti-tumor immune responses is crucial for cancer progression. Immune checkpoint blockade (ICB), which can potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor immunity. In recent years, immune checkpoints, expressed on both tumor cells and immune cells, have been identified; some of them have exhibited potential druggability and have been approved by the US Food and Drug Administration (FDA) for clinical treatment. However, limited responses and immune-related adverse events (irAEs) cannot be ignored. This review outlines the development and applications of ICBs, potential strategies for overcoming resistance, and future directions for ICB-based cancer immunotherapy. 抗肿瘤免疫反应的功能缺陷对癌症进展至关重要。免疫检查点阻断(ICB)可增强T细胞反应,是宿主抗肿瘤免疫正常化的有效策略。近年来,多项表达于肿瘤细胞和免疫细胞的免疫检查点已被鉴定,其中一些显示出良好的成药性,并已获得美国食品药品监督管理局(FDA)的批准用于临床治疗。然而,有限的治疗反应和免疫相关不良事件(irAEs)不容忽视。本文综述了ICB的发展和应用,并就基于ICB的癌症免疫疗法克服耐药性的潜在策略和未来方向展开讨论。.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsImmunotherapyHumansAnimals

Stichwörter der Autor:innen

Cancer immunotherapyImmune checkpoint blockadeImmune normalizationTumor immune evasion

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province, Hangzhou 310058, China.
  • Department of Biochemistry, Zhejiang University School of Medicine, Hangzhou 310058, China. yinshi@zju.edu.cn.
  • Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China. wqq@zju.edu.cn.
  • The Key Laboratory for Immunity and Inflammatory Diseases of Zhejiang Province, Hangzhou 310058, China. wqq@zju.edu.cn.

Förderung

  • the National Key Research and Development Program of China
  • the National Natural Science Foundation of China

Zitieren

APA

Ye, H., Liao, W., Pan, J., Shi, Y., & Wang, Q. (2025). Immune checkpoint blockade for cancer therapy: current progress and perspectives. Journal of Zhejiang University-SCIENCE B, 26(3), 203-226. https://doi.org/10.1631/jzus.b2300492

Vancouver

Ye H, Liao W, Pan J, Shi Y, Wang Q. Immune checkpoint blockade for cancer therapy: current progress and perspectives. Journal of Zhejiang University-SCIENCE B. 2025;26(3):203-226. doi:10.1631/jzus.b2300492

BibTeX
@article{Ye2025,
  author = {Ye, Hongying and Liao, Weijie and Pan, Jiongli and Shi, Yin and Wang, Qingqing},
  title = {Immune checkpoint blockade for cancer therapy: current progress and perspectives},
  journal = {Journal of Zhejiang University-SCIENCE B},
  year = {2025},
  volume = {26},
  number = {3},
  pages = {203--226},
  doi = {10.1631/jzus.b2300492}
}
Kostenlos starten →